Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC By Ogkologos - April 9, 2025 598 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Science Surgery: ‘Can cancers develop in the heart?’ March 30, 2021 FDA Approval of Rylaze Will Address Drug Shortage for Childhood ALL July 29, 2021 Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in... September 16, 2024 Grieving for Your Old Life After Cancer September 10, 2020 Load more HOT NEWS Comme louer son affaire en compagnie de tacht mahometane? (2023) Zanidatamab Demonstrates Meaningful Clinical Benefit with a Manageable Safety Profile in... FDA Approves Vorasidenib for Grade 2 Astrocytoma or Oligodendroglioma with a... Pembrolizumab Plus Axitinib Outperforms Sunitinib in Patients with Metastatic Renal Cell...
